$422 Million is the total value of MPM BioImpact LLC's 38 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEO | Exit | Neogenomics Inc. | $0 | – | -135,573 | -100.0% | -0.31% | – |
| KRTX | Exit | Karuna Therapeutics inc | $0 | – | -20,000 | -100.0% | -0.70% | – |
| EPZM | Exit | Epizyme, Inc. | $0 | – | -3,425,202 | -100.0% | -1.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.